

Original Research Article

Antibacterial^{microbial} Susceptibility of Urinary *Escherichia coli* from Outpatients with Community Acquired Urinary Tract Infections, Report from Tertiary Health Care Center, Egypt.

Abstract:

Background: *Escherichia coli* are the main etiology agent of urinary tract infections (UTIs). Antibacterial resistance spreads rapidly among community acquired urinary *E. coli*. (Recast too short)

Objectives: The aim of this prospective study was to describe antibiotic antimicrobial susceptibility profile and prevalence of multidrug resistant (MDR) urinary *E. coli* isolated from outpatients with community acquired UTI.

Methods: Urine samples were collected from patients attending outpatient departments of Mansoura University Hospitals in Egypt presented with symptoms of UTI. Samples were cultured and *E. coli* isolates were identified by colony^{ial} morphology, Gram stained film, and analytical profile index (API) 20E. Antibiotic sensitivity testing was performed by standard Kirby-Bauer disk diffusion method.

Results: One hundred and forty one *E coli* uropathogen were isolated. The highest resistance was to beta lactam antibiotics. Amoxicillin susceptibility was 2.1%. Resistance to 3rd generation cephalosporins was (57.4%, 40.4%, 46.8% to cefotaxime, ceftazidime, and cefoperazone) respectively. The resistance to norfloxacin was (46.8%). While R^{resistance} to nitrofuantoin was (27.7%). The least resistance was to cefoperazone-sulbactam and amikacin (8.5% and 12.8% respectively). Most of the isolates were multidrug resistant (87.9%).

Conclusion: High level of antibiotic resistance among *E. coli* causing community acquired urinary tract infection.

Key words: Urinary tract infection, *Escherichia coli*, Antibacterial resistance, Multidrug resistant.

Introduction

Urinary tract infection (UTI) remains one of the most common community acquired infections which necessitate the prescription of empirical antibiotics [1]. *Escherichia coli* is the most important uropathogen which cause about 80% of these infections [2-3]. The high incidence of UTI caused by *E. coli* is linked to its presence among facultatively anaerobic flora of the gastrointestinal tract. From there, seeding occurs to urogenital areas such as the vaginal interoitus, the periurethral area, and the male prepuce, providing a local site for introduction and subsequent development of ascending UTI [4]. In nearly all cases of (Expunge) cCommunity acquired UTIs treatment is empirically, as the result of antimicrobial susceptibility testing are usually reported after 48h 72hr. Antibiotics like trimethoprim-sulfamethoxazole, quinolones, cephalosporins, semi-synthetic penicillins with or without inhibitors, gentamicin and nitrofurantoin, are used widely used as empirical treatment for community acquired UTIs [5-7] . The inappropriate prescribing of broad spectrum antibiotics leads to the increased resistance to important groups like fluoroquinolones and cephalosporins [8-9]. In addation to the rapid emergence of multidrug resistance (MDR) *E. coli* which is associated with poor clinical outcomes and lower cure rates [10-11]. For proper empirical therapy and prevention of antibiotic resistance, it is essential to evaluate the antibiotic sensitivity of the common etiological agents which differ from country to country according the antibiotic usage [12, 13].

Few studies reported resistance pattern of urinary *E. coli* and prevalence of MDR among patients with community acquired UTI in Egypt. The present study was performed to identify antibiotic susceptibility profiles of *E. coli* implicated in community acquired UTIs among patients attending outpatient departments of Mansoura University Hospitals (Mansoura, Egypt).

Methods

This study was performed in outpatient departments of Mansoura University Hospitals in Egypt during period extending from March 2014 to December 2015. A total of 270 urine samples were collected from patients presented with symptoms of urinary tract infection (burning, urgency, and frequency). Urine sample is collected from the same patient only after 3 month of the initial positive culture. Patients previously admitted to hospital in the last 2 weeks and catheterized were excluded. Midstream urine samples were collected using clean catch technique in sterile container, after instructing patients for washing the perennial area. Early morning samples were collected as possible. Collected samples were stored at 4° C till they were transported to Microbiology Lab in faculty of medicine, Mansoura Univerisity. Samples were inoculated on cystine lactose electrolyte deficient (CLED) agar using calibrated loop (10μ). Cultures were incubated for 24hr at 37°C, and they were considered positive if colony counts $\geq 10^5$ CFU/ ml. *E. coli* was identified by colonyial morphology, Gram stained film, and API 20E (bioMerieux, Marcy-l'Etoile, France) [14]. Antibiotic sensitivity testing was done by standard Kirby-Bauer disk diffusion method, on Mueller-Hinton agar (oxid) medium [15].

We considered the isolates not susceptible to one or more agents of at least 3 antimicrobial groups as MDR. The tested antibiotics were classified into groups: penicillins (amoxicillin) non-extended spectrum cephalosporins (cefuraxime, and cefaclor), extended-spectrum cephalosporines (cefotaxime, cefoperazone, ceftazidime, and cefpime), penicillin beta latamse

inhibitor (amoxicillin-clavulanic acid, ampicillin-sulbactam), cephalosporine beta lactamase inhibitor (cefoperazone-sulbactam), aminoglycosides (gentamicin and amikacin), quinolones (norfloxacin), nitrofurans (nitrofurantoin), trimethoprim-sulphamethoxazole , and nalidixic acid [16]. All antibiotic discs were obtained from (Oxoid manufactures).

The Statistical Package for the Social Sciences (SPSS) 16.0 for Windows was used for statistical analyses. Descriptive statistics was described as mean, standard deviation (s.d), minimum, maximum and percentage.

Results

A total of one hundred and forty one *E. coli* strains were isolated from 270 urine sample collected from patients presented with symptoms with UTI during period extending from March 2014 to December 2015 in outpatient departments of Mansoura University Hospitals. *E. coli* strains were isolated from 120 female patients (85.1%) and 21 male patients (14.9%). The mean age was 32 years (range 4-70 years). Female patients aged from (15-40 years) represent the major sector (44.7%) table (1). All male patients were aged above 40 years (Authors information here are not detail enough; this is the number of subjects that take part in the research. Authors should make known their observation in each age class or groups in the research both subjects with positive and negative isolates. Also, the table is too compressed vital information were suppressed authors should review the table statistics appropriately such as 10-15, 16-20, 21-25, 26-30 e.t.c. This will show detail revelation of isolates without bias). The least resistance was to cefoperazone-sulbactam (8.5%) and the highest was to amoxicillin (97.9%). Regarding 3rd generation cephalosporins, the resistance pattern to cefotaxime, cefoperazone and ceftazidime was (57.4%, 46.8%, and 40.4% respectively). Resistance to norfloxacin was 46.8%. Resistance and to nitrofurantoin was (27.7%). The resistance to beta lactam- beta lactamase inhibitor

combinations was (48.9% and 59.6%) to amoxicillin clavulanic acid and ampicillin-sulbactam respectively. Amikacin resistance was lower than gentamicin (12.8% versus 29.8%) table (2). Majority of the isolates were MDR (87.9%).

Table (1) Patients' characters (Table 1, not detail enough)

Sex	NO (%)
Male	21 (14.9)
Female	120 (85.1)
Age	
Mean $\pm$ SD (min-max)	32 $\pm$ 20.9 (4-70)
Age groups	NO (%)
<15	36 (25.5)
15-40	63 (44.7)
>40	42 (29.8)

Table (2) antibiotic sensitivity pattern of *E. coli* isolates (Interchanging resistance and sensitivity is confusing to readers)

	S	I	R
	NO%	NO%	NO%
Amoxiacillin	3 (2.1)	-	138 (97.9)
Cefaclor	9 (6.4)	3 (2.1)	129 (91.5)

Cefuraxime	27 (19.1)	15 (10.6)	99 (70.2)
Cefotaxime	54 (40.4)	6 (4.3)	81 (57.4)
Ceftazidime	57 (40.4)	27 (19.1)	57 (40.4)
Cefoperazon	54 (38.3)	21 (14.9)	66 (46.8)
Cefpime	96 (68.1)	12 (8.5)	33 (23.4)
Cefoperazone- sulbactam	126 (89.4)	3 (2.1)	12 (8.5)
Norfloxacin	75 (53.2)	-	66 (46.8)
Gentamicin	93 (66)	6 (4.3)	42 (29.8)
Amikacin	93 (66)	30 (21.3)	18 (12.8)
Nalidixic acid	27 (19.1)	3(2.1)	111 (78.7)
Nitrofurantoin	84 (59.6)	18 (12.8)	39 (27.7)
Trimethoprim- sulphamethoxazole	27 (19.1)	12 (8.5)	102 (72.3)
Amoxacillin- clavulanic acid	42 (29.8)	30 (21.3)	69 (48.9)
Ampicillin-sulbactam	42 (29.8)	15 (10.6)	84 (59.6)

S: susceptible I: intermediate R: resistant

Discussion:

The majority of urinary *E. coli* were from female patients 120 (85.1%), sixty three (44.7%) were in the child bearing period (15-40). This result is expected as females especially in reproductive age are in higher risk for UTI than males [17-18]. This result agrees with most studies in other countries like Ethiopia, Nigeria, and Iran [19-21]. Antibiotics belong to beta

lactams and fluroquinolones groups are the most widely used agents for empirical therapy of UTI [22]. The current study finds high rates of resistance to amoxicillin about 98%. This result confirms Infectious Diseases Society of America (IDSA) guidelines, it better to avoid use of amoxicillin in treatment of UTI due to poor efficacy [1]. Regarding extended spectrum cephalosporins; the least resistance was to fourth generation agent cefpime and 3rd generation ceftazidime (23.4% and 40.4%) respectively. Resistance to fluroquinolones agent (norfloxacin) in this study was (46.8). This result is similar to other previous results like kresken et al and Sanchez et al [23-24]. Trimathoprim-sulfamethoxazole which an agent used widely for treatment of UTI, have high resistance (72.3%). This result is consistent with results of studies in other areas by Mamani et al and Rasamiravaka et al [21, 25]. This high resistance may be due to overuse of these antibiotics as a self medication, or over prescription by private pharmacies and clinics. Most patients did not ask medical advice in hospital except after failure of these therapies. In addition, these agents are used widely as an empirical treatment for other community associated infections like upper respiratory tract and GIT infections. This over use of antibiotics leads to development of resistance as reported previously [26]. As a part of gut flora, *E. coli* was exposed to selective pressure produced by antibiotic overusage [27]. Lower resistance rates were described in areas that restrict use of these antibiotics in community setting, for example amoxicillin resistance which range from ranges 48% in Netherland to 60% in Belgium [28]. In our study, we test one antibiotic agent which not used as empirical therapy or self therapy; cefoperazone-sulbactam. The resistant to this agent was only (8.5%). This augments our explanation for the higher rates of resistance described for other agents. High prevalence of MDR bacteria was obtained relative to other studies. This is an expected result due to higher resistance to antimicrobial agents also may

be due to the inclusion of the intermediate group in the definition of MDR. This study has some limitations. First, the lack of medical data about the patients like DM and other chronic illness which represent risk factors for recurrent infections and repeated antibiotic courses. Second, the study did not investigate the type of UTI upper or lower. Furthermore, we did not test for extended spectrum beta lactamases which represents important cause of antibiotic resistance. However, our study presents preliminary information about the state of antibiotic resistance community acquired *E. coli* causing UTI.

Conclusion:

High level of antibiotic resistance to beta lactam antibiotics among *E. coli* causing community acquired urinary tract infection was detected. While agents like Nitrofurantoin is still retaining some activity against this organism. Multidrug resistant *E. coli* is a serious problem in community setting.

Ethical approval

Ethical approval was given by local Ethical Committee **in** Mansoura Faculty of Medicine (Mansoura, Egypt).

References:

1. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, *et al.* International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:103–20.
2. Kahlmeter G; ECO.SENS. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project . J Antimicrob Chemother 2003 ; 51: 69 – 76.

3. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: A population-based assessment. *Infection*. 2007; 35: 150–3.
4. Janda MJ, Abbott SL. *Escherichia coli*. In Janda, M. J., Abbott, S.L. (eds). *The Enterobacteria*, Lippincott-Raven. Philadelphia, New York. P.P. 13-61.
5. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. *Infectious Diseases Society of America (IDSA). Clin Infect Dis* 1999; 29:745–58.
6. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. *Eur Urol* 2008; 54:1164–75.
7. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B *et al*. Antibiotic resistance in *Escherichia coli* outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). *Int J Antimicrob Agents* 2006; 27:468–75.
8. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase producing *Enterobacteriaceae*: an emerging public-health concern. *Lancet Infect Dis*. 2008;8:159–66.
9. Cassier P1, Lallechère S, Aho S, Astruc K, Neuwirth C, Piroth L, Chavanet P. Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β -lactamase-producing *Escherichia coli*: a case-control study in a French teaching hospital. *Clin Microbiol Infect* 2011;17(11):1746-51.

10. Sahm DF, Brown NP, Yee YC, Evangelista AT. Stratified analysis of multidrug-resistant *Escherichia coli* in US health care institutions. *Postgrad Med* 2008; 120: 53–9.
11. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09. *J Antimicrob Chemother* 2014; 69: 234–40.
12. Aypak C, Altunsoy A, Düzgün N. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study. *Ann Clin Microbiol Antimicrob* 2009; 8:27.
13. Kahlmeter G. The ECO_SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. *J Antimicrob Chemother* 2000; 46 (Suppl A):15–22.
14. Chessbrough M. Collection, transport and examination of specimens. In: Chessbrough M, ed. *Medical laboratory Manual for Tropical countries*. Butterworth-Heinemann, Oxford, 1993; 100-95.
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: 23rd informational supplement. CLSI document M100-S23. Wayne, PA: CLSI; 2013.
16. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, *et al.* Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012; 18(3) :268-81.

17. Fauci AS, Brunwald E, Kasper DL, Longo DL, Hauser SL, Jameson JL *et al.* Disorder of the urinary and kidney tract. In Harrison's ed.: Principles of Internal Medicine. McGraw-Hill Companies; 2008:18.
18. Griebing TL. Urinary Tract Infection in Women. In: Litwin MS, Saigal CS ed. In Urologic Disease in America. Washington, DC: NIH Publication, 2007; 587–619.
19. Abejew AA, Denboba AA, Mekonnen AG. Prevalence and antibiotic resistance pattern of urinary tract bacterial infections in Dessie area, North-East Ethiopia. BMC Research Notes 2014; 7:687.
20. Jombo GT, Emanghe UE, Amefule EN, Damen JG. Urinary tract infections at a Nigerian university hospital: causes, patterns and antimicrobial susceptibility profile. J Microbiol Antimicrob 2011; 3:153–9.
21. Mamani M, Nobari N, Alikhani MY, Poorolajal J. Antibacterial susceptibility of *Escherichia coli* among outpatients with community-acquired urinary tract infection in Hamadan, Iran. J Glob Antimicrob Resist. 2015; 3:40–3.
22. Aypak C, Altunsoy A, Düzgün N. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study. Ann Clin Microbiol Antimicrob. 2009; 8:27.
23. Kresken M, Pfeifer Y, Hafner D, Wresch R, Körber-Irrgang B; Working Party 'Antimicrobial Resistance' of the Paul-Ehrlich-Society for Chemotherapy. Occurrence of multidrug resistance to oral antibiotics among *Escherichia coli* urine isolates from outpatient departments in Germany: extended-spectrum β -lactamases and the role of fosfomycin. Int J Antimicrob Agents. 2014; 44(4):295-300.

- 218 24. Sanchez GV, Baird AM, Karlowsky JA, Master RN, Bordon JM. Nitrofurantoin
219 retains antimicrobial activity against multidrug-resistant urinary *Escherichia coli* from
220 US outpatients. *J Antimicrob Chemother.* 2014; 69(12):3259-62.
- 221 25. Rasamiravaka T, Sheila HS, Rakotomavojaona T, Rakoto-Alson
222 AO, Rasamindrakotroka A. Changing profile and increasing antimicrobial resistance
223 of uropathogenic bacteria in Madagascar. *Med Mal Infect.* 2015; 45(5):173-6.
- 224 26. Baquero F, Negri MC, Morosini MI, Blázquez J. Antibiotic selective environments.
225 *Clin. Infect. Dis.* 1998; 27(Suppl 1):S5–S11.
- 226 27. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic
227 prescribing in primary care on antimicrobial resistance in individual patients:
228 systematic review and meta-analysis. *BMJ.* 2010; 340:c2096.
- 229 28. Van der Donk CF, Van de Bovenkamp JH, De Brauwier EI, De Mol P, Feldhoff
230 KH, Kalka-Moll WM *et al.* Antimicrobial resistance and spread of multi drug
231 resistant *Escherichia coli* isolates collected from nine urology services in the
232 Euregion Meuse-Rhine. *PLoS One* 2012; 7(10):e47707.